Duloxetine in the Treatment of Melancholic Depression
Duloxetine in the Treatment of Melancholic Depression: An 8-Week Open-Label Dose Study
Sponsor: Eli Lilly and Company
This PHASE3 trial investigates Depressive Disorder, Major and is currently completed. Eli Lilly and Company leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
May 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beauport, Canada , Calgary, Canada , Edmonton, Canada , Elizabeth Vale, Australia , Everton Park, Australia , Greater Sudbury, Canada , Halifax, Canada , Hoppers Crossing, Australia , Kingston, Canada , London, Canada and 13 more locations